Glenmark Pharmaceuticals Ltd.
Price
Daily candles · NSEWhat the numbers say
- Low return on equity: 3-year ROE 1.8%.
- Comfortable leverage: debt-to-equity of 0.00.
- Sales compounded at 13.6% over 3 years.
- Weak cash conversion (CFO/OP 0.25).
- Trades above its industry P/E (45.6 vs 25.9).
Generated automatically from reported financials. These are observations, not a recommendation to buy or sell.
- Glenmark Pharmaceuticals’ arm launches Adapalene Gel USP in new pump packs
Glenmark’s Adapalene Gel USP, 0.1% can be compared to the active ingredient of Differin Gel, 0.1%
- Glenmark Pharmaceuticals gets EIR with VAI status for Goa facility
The inspection was conducted at the company’s manufacturing facility from June 22, 2026 to June 30, 2026
- Glenmark Pharmaceuticals’ arm launches RYALTRIS Nasal Spray in Brazil
The launch follows regulatory approval granted by the Brazilian Health Regulatory Agency, Agencia Nacional de Vigilancia Sanitaria earlier this year
- Glenmark Pharmaceuticals’ arm launches Calcium Gluconate Injection
The Calcium Gluconate Injection, 1,000 mg/10 mL, 5,000 mg/50 mL and 10,000 mg/100 mL market achieved annual sales of around $69.9 million.
- Glenmark Pharma gets USFDA’s nod for Fluticasone Propionate Nasal Spray
According to IQVIA sales data for the 12-month period ending June 2026, the Flonase Nasal Spray market achieved annual sales of around $295.2 million
- Glenmark Pharmaceuticals’ arm launches Sugammadex Injection
Glenmark’s Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION Injection, 100 mg/mL of Merck Sharp & Dohme LLC
- Glenmark Pharma’s arm gets USFDA’s nod to expand use of RYALTRIS Nasal Spray
The approval was supported by a Phase 3, randomized, double-blind, placebo-controlled study involving 446 children aged 6 to 11 years with Seasonal Allergic Rhinitis
- Glenmark Pharmaceuticals’ arm launches Olanzapine for Injection
The launch of Olanzapine for Injection underscores its strategic focus on growing a robust injectables portfolio and strengthening its presence within the institutional channel
Company announcements as filed with the exchanges. Reproduced for information — not a view or a recommendation.
| Profit & Loss · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Net Sales | 16,983 | 13,322 | 11,813 | 11,583 | 12,305 |
| Other income | 461 | 114 | 840 | 289 | 167 |
| Total Income | 17,443 | 13,435 | 12,653 | 11,872 | 12,472 |
| Expenditure | 12,410 | 10,970 | 10,618 | 9,948 | 9,985 |
| Operating Profit | 5,033 | 2,465 | 2,035 | 1,924 | 2,487 |
| Interest | 209 | 207 | 516 | 349 | 298 |
| Depreciation | 573 | 486 | 582 | 569 | 487 |
| Profit before tax | 1,985 | 1,399 | 36 | 240 | 1,441 |
| Tax | 623 | 352 | 1,867 | 329 | 448 |
| Net Profit | 1,362 | 1,047 | -1,831 | -90 | 994 |
| EPS (₹) | 48.26 | 37.11 | -53.22 | — | 33.37 |
| Net margin % | 8.0 | 7.9 | -15.5 | -0.8 | 8.1 |
Consolidated figures, as filed with the exchanges. Newest year first. EPS for FY23 is not shown: the value supplied does not agree with the number of shares the company reported for that year, and we would rather show nothing than a figure we cannot reconcile.
| Balance Sheet · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Equity capital | 28 | 28 | 28 | 28 | 28 |
| Reserves | 10,450 | 8,812 | 7,801 | 9,428 | 9,042 |
| Net worth | 10,478 | 8,840 | 7,830 | 9,456 | 9,070 |
| Total sources | 13,530 | 10,024 | 8,540 | 14,825 | 12,362 |
| Net block | 5,915 | 4,487 | 4,210 | 5,422 | 5,887 |
| Capital work in progress | 909 | 835 | 662 | 1,190 | 1,010 |
| Investments | 538 | 308 | 1,009 | 229 | 218 |
| Inventory | 3,431 | 3,029 | 2,513 | 2,374 | 2,500 |
| Debtors | 4,963 | 3,342 | 1,858 | 3,665 | 3,101 |
| Cash & bank | 1,176 | 1,705 | 1,659 | 1,160 | 1,412 |
| Book value (₹) | 371.30 | 313.28 | 277.46 | 335.13 | 321.45 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Cash Flow · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| From operations | 3,445 | -828 | -265 | 625 | 1,109 |
| From investing | -1,283 | 2 | 4,561 | -528 | -333 |
| From financing | -2,709 | 787 | -3,906 | -77 | -520 |
| Net change in cash | -547 | -38 | 389 | 19 | 255 |
| Free cash flow | 2,162 | -826 | 4,295 | 97 | 775 |
| Closing cash | 1,175 | 1,676 | 1,658 | 1,443 | 1,411 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Ratios | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| ROCE % | 20.4 | 16.2 | 4.9 | 4.4 | 14.2 |
| ROE % | 14.1 | 12.6 | -21.2 | -1.0 | 12.3 |
| PAT margin % | 3.9 | 3.6 | -6.6 | -0.3 | 3.6 |
| EBIT margin % | 6.3 | 5.6 | 2.0 | 2.1 | 6.3 |
| Debt / equity | 0.00 | 0.25 | 0.13 | 0.46 | 0.40 |
| Current ratio | 1.77 | 1.56 | 1.28 | 1.85 | 1.77 |
| Interest cover | 10.51 | 7.76 | 1.07 | 1.69 | 5.83 |
| Sales growth % | 27.5 | 12.8 | 2.0 | -5.9 | 12.4 |
| Dividend per share (₹) | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 |
| Payout % | 5.2 | 6.7 | -4.7 | 23.7 | 7.5 |
Consolidated figures, as filed with the exchanges. Newest year first.
Frequently asked
Glenmark Pharmaceuticals Ltd. (GLENMARK) last traded at ₹2,198.50 on the NSE, up +0.20% on the session. Prices on this page are indicative and for information only.
Glenmark Pharmaceuticals Ltd. has traded between ₹1,792.60 and ₹2,537.60 over the last 52 weeks on the NSE.
Glenmark Pharmaceuticals Ltd. has a market capitalisation of about ₹62,042 crore.
Glenmark Pharmaceuticals Ltd. trades at a P/E of 45.6, against an industry P/E of 25.9.
Open a trading and Demat account with Labdhi — it is fully digital with paperless KYC — then place a buy order for GLENMARK from the Labdhi app or web platform.
Yes. You can invest in equities in a staggered manner through Labdhi. Speak to your Labdhi adviser about a plan suited to your goals and risk profile.
Who is actually trading it
Delivery against churn, the deals big enough to be reported, what the insiders did, and the benchmarks that hold Glenmark Pharmaceuticals Ltd..
Loading trading activity…
Exchange filings and end-of-day data, not a live feed. Bulk, block and insider records are published by the exchanges when a threshold is crossed, so they show reportable activity only. For information, not a recommendation to deal, and not a view on any person named above.
Disclosures. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Prices and data on this page are indicative and for information only. Nothing here is investment advice or a recommendation to buy or sell any security. Investors should consider their own objectives, financial situation and risk profile, and may wish to seek independent advice, before investing.
Figures are as reported by the company; consolidated where available. Errors and omissions excepted.
L. F. C. Securities Pvt. Ltd. · Member BSE, NSE, MCX · SEBI Stock Broker INZ000170736 · CDSL IN-DP-281-2016 · AMFI ARN-78991 · Investment Adviser (Non-Individual) INA000011617 · Compliance Officer: Mr. Santosh Patil · santoshp@labdhi.in · 022-35006933 · Investor Grievances: investorgreve@labdhi.in